Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,422.00
Bid: 12,420.00
Ask: 12,422.00
Change: 76.00 (0.62%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,430.00
Low: 12,322.00
Prev. Close: 12,346.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: London Set For Soft Opening With US Jobs In Focus

Fri, 06th Mar 2015 07:34

LONDON (Alliance News) - UK stocks are set to open a touch lower Friday as investors continue to digest European Central Bank President Mario Draghi's comments at the ECB's monetary policy press conference Thursday and await the US non-farm payrolls report due in the afternoon.

Draghi on Thursday said the ECB will start purchasing public sector bonds in the secondary market this coming Monday, March 9, under its USD1.1 trillion quantitative easing scheme announced in January. He reiterated that monthly purchases under the QE plan will be EUR60 billion and they will be carried out until the end of September 2016 "and will, in any case, be conducted until we see a sustained adjustment in the path of inflation which is consistent with our aim of achieving inflation rates below, but close to, 2% over the medium term."

Draghi added that the ECB will purchase bonds with negative yields up to the deposit rate of -0.2%.

He also said inflation in the eurozone is likely to fall to zero in 2015, lower than the 0.7% projected previously. It is expected to pick up to 1.5% in 2016 and to 1.8% in 2017. Economic growth forecasts for this year were raised to 1.5% from the 1.0% seen in December. The growth projection for next year was boosted to 1.9% from 1.5%.

The euro rose to a two-day high against the dollar as Draghi began his prepared comments, before falling to a fresh 11-year low at USD1.1005 as he answered questions from journalists. Ahead of the open on Friday the euro remains weak against the dollar, trading at USD1.1016.

IG futures indicate the FTSE 100 to open 5.8 points lower at 6,955.3. The index closed up 0.6% at 6,961.14 Thursday, a new record closing high for the index.

Wall Street also closed higher Thursday, with the DJIA ending up 0.2%, the S&P 500 closed up 0.1%, and the Nasdaq Composite ended up 0.3%.

In Asia Friday, the Japanese Nikkei closed up 1.2%, while the Hang Seng and the Shanghai Composite both trade down 0.2%.

German industrial production in January rose by more than expected, according to figures released early Friday. The seasonally adjusted figure rose by 0.6%, outstripping the expectation of a 0.5% growth. December's production growth was revised up to 1.0% from 0.1%.

AstraZeneca guided that it expects its total revenue to decline by a mid-single digit percentage at constant exchange rates in 2015, in line with previous sales revenue guidance it gave at the time of its full-year results, as it announced changes to the way it presents its revenue. The pharmaceutical giant has maintained its core earnings per share guidance.

Thomas Cook Group said it has struck a strategic deal with Chinese investment group Fosun International Ltd under which the latter will acquire a 5% stake in the travel operator. Thomas Cook said Fosun will pay GBP91.8 million to acquire 73.1 million shares Thomas Cook will issue to it, giving Fosun a 5% stake in the company. The shares are valued at 125.58 pence, compared to the travel firm's closing price Thursday of 120.60p.

Fosun then intends to acquire further Thomas Cook shares via open market purchases, with plans to increase its shareholding in the company to around 10% of its enlarged share capital.

In the economic calendar Friday, the focus will be on US nonfarm payrolls, unemployment rate and earnings data at 1330 GMT. Before that is UK consumer inflation expectations at 0930 GMT and eurozone fourth quarter GDP at 1000 GMT.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.